Express News | Johnson & Johnson Shares Down 0.2% in Volume Spike Following Bloomberg Report It Secured Plantiff Backing for $6.5 Bln Baby Power Accord
Express News | J&J Gets Plaintiff Backing for $6.5 Billion Baby Powder Accord- Bloomberg News
Johnson & Johnson Clears Key Hurdle to Resolve Baby Powder Lawsuits, Bloomberg Reports
Express News | J&J Secures Plaintiff Support For $6.5 Billion Baby Powder Settlement Accord
FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates -- Barrons.com
Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies
Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ
Gilead Exits J&J Royalty Deal for Liver Drug Ahead of Potential FDA Nod
Healthcare Stocks Are Closing the Gap. Here Are the Latest Winners.
J&J, Stryker Among Potential Suitors for Nevro: Wolfe
Johnson & Johnson Announces Groundbreaking Nipocalimab Study Of Pregnant Individuals At High Risk For Early Onset Severe Hemolytic Disease Of The Fetus And Newborn Published In The New England Journal Of Medicine
Express News | J&J - Labeling Update for Linx Reflux Management System Will Provide More Patients Relief From Gastroesophageal Reflux Disease
Express News | Johnson & Johnson Medtech Announces Labeling Amendment of Linx™ Reflux Management System in U.S. to Include Patients With Barrett's Esophagus Experiencing Gastroesophageal Reflux Disease
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Johnson & Johnson's (NYSE:JNJ) Investors Will Be Pleased With Their Favorable 37% Return Over the Last Five Years
Groundbreaking Nipocalimab Study of Pregnant Individuals at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn Published in The New England Journal of Medicine
Benadryl Parent's Stock Soars as Allergy Season Got a Lot Worse, Boosting Sales
Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Kenvue's Stock Soars After Band-Aid, Tylenol Parent's Profit Surprisingly Rose